LEADER 03554nam 22006254a 450 001 9910830425203321 005 20170809162023.0 010 $a1-280-64906-2 010 $a9786610649068 010 $a0-470-05217-1 010 $a0-470-05215-5 035 $a(CKB)1000000000354776 035 $a(EBL)272151 035 $a(SSID)ssj0000163985 035 $a(PQKBManifestationID)11163742 035 $a(PQKBTitleCode)TC0000163985 035 $a(PQKBWorkID)10140299 035 $a(PQKB)11785210 035 $a(MiAaPQ)EBC272151 035 $a(OCoLC)85784708 035 $a(EXLCZ)991000000000354776 100 $a20060302d2006 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aGlycogen synthase kinase 3 (GSK-3) and its inhibitors$b[electronic resource] $edrug discovery and development /$fedited by Ana Martinez, Ana Castro, Miguel Medina 210 $aHoboken, N.J. $cWiley-Interscience$dc2006 215 $a1 online resource (388 p.) 225 1 $aWiley series in drug discovery and development 300 $aDescription based upon print version of record. 311 $a0-471-77001-9 320 $aIncludes bibliographical references and index. 327 $aGlycogen synthase kinase 3: an introductory synopsis -- Glycogen synthase kinase-3[beta] (GSK-3[beta]) a key signaling enzyme: a developmental neurobiological perspective -- Role of GSK-3/Shaggy in neuronal cell biology -- The crystal structures of glycogen synthase kinase 3 -- Kinase-kinase and site-site interactions in the phosphorylation of tau by GSK-3 -- GSK-3, a key player in Alzheimer's disease -- Glycogen synthase kinase 3 : a target for novel mood disorder treatments -- GSK-3 and stem cells -- Glycogen synthase kinase 3 : role in neurodegeneration and neuroprotection -- 327 $aProtein kinase assays for drug discovery -- Animal models with modified expression of GSK-3 for the study of its physiology and of its implications in human pathologies -- Lithium, the seminal GSK-3 inhibitor -- Inhibition of GSK-3 as therapeutic strategy in disease : efficacy of AR-A014418 -- TDZD's: selective and ATP noncompetitive glycogen synthase kinase 3 inhibitors -- 3-amino pyrazoles as potent and selective glycogen kinase synthase (GSK-3) inhibitors -- Marine compounds as a new source for glycogen synthase kinase 3 inhibitors. 330 $aMany researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It's a great reference for researchers in drug design and development. 410 0$aWiley series in drug discovery and development. 606 $aGlycogen synthase kinase-3 606 $aGlycogen synthase kinase-3$xInhibitors 615 0$aGlycogen synthase kinase-3. 615 0$aGlycogen synthase kinase-3$xInhibitors. 676 $a547.12 676 $a572.567 676 $a572/.567 701 $aMarti?nez$b Ana$f1961-$01659284 701 $aCastro$b Ana$01659285 701 $aMedina$b Miguel$f1959-$01659286 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830425203321 996 $aGlycogen synthase kinase 3 (GSK-3) and its inhibitors$94013863 997 $aUNINA